Review Article: The Evolving Role of GLP-1 Receptor Agonists in Gastroenterology Practice.
Level 5 - mechanism / opinion, no new human data
Narrative review synthesizing clinical trials, cohort studies, and guidelines without systematic methodology.
PubMed 41215723 · doi:10.1111/apt.70450
What was done
Authors conducted a narrative review of clinical trials, cohort studies, and guideline updates published through 2025. The review synthesized evidence on the efficacy, safety, and practice implications of GLP-1 receptor agonists across gastrointestinal disorders, including steatotic liver disease, gastroesophageal reflux, inflammatory bowel disease, short bowel syndrome, and obesity-associated cancers.
What was found
The abstract reports no numerical data or effect sizes. Qualitatively, GLP-1 receptor agonists produced weight loss and improved obesity-related gastrointestinal outcomes, showing histologic and biochemical benefits in steatotic liver disease and an association with reduced incidence of several GI cancers. Frequently reported adverse events were nausea, vomiting, diarrhoea, constipation, and delayed gastric emptying, accompanied by substantial discontinuation rates that may be mitigated by careful titration.
Why it matters
This review outlines the growing indications and management considerations for GLP-1 receptor agonists within gastroenterology, highlighting peri-endoscopic precautions and adverse effect monitoring.
Limits
The abstract provides no quantitative metrics or study counts. As a narrative review rather than a systematic review or meta-analysis, the synthesis lacks structured risk-of-bias grading and reproducible literature retrieval criteria.
Cited by
- supports Eating large solid meals close to bedtime while on GLP-1 receptor agonists leads to severe heartburn and gastrointestinal discomfort due to delayed gastric emptying.